Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Eagle Health Investments LP

Eagle Health Investments LP trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 11.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 343,361 shares of the life sciences company's stock after selling 43,993 shares during the quarter. Illumina accounts for about 11.2% of Eagle Health Investments LP's portfolio, making the stock its 3rd largest position. Eagle Health Investments LP owned approximately 0.22% of Illumina worth $45,883,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Versant Capital Management Inc lifted its stake in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after buying an additional 146 shares during the period. Golden State Wealth Management LLC purchased a new position in Illumina in the 4th quarter worth $32,000. Assetmark Inc. lifted its position in Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after acquiring an additional 296 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Illumina during the 4th quarter valued at about $45,000. Finally, Lee Danner & Bass Inc. acquired a new position in shares of Illumina in the fourth quarter valued at about $48,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Price Performance

ILMN traded down $2.28 during midday trading on Friday, hitting $80.00. 1,526,373 shares of the company traded hands, compared to its average volume of 2,212,008. The company has a market capitalization of $12.67 billion, a price-to-earnings ratio of -10.42, a PEG ratio of 1.60 and a beta of 1.17. The business has a 50 day simple moving average of $102.80 and a two-hundred day simple moving average of $126.81. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 52-week low of $79.30 and a 52-week high of $156.66.

Remove Ads

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, equities analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the topic of a number of recent research reports. Robert W. Baird dropped their target price on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 5th. Hsbc Global Res downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. Royal Bank of Canada reduced their target price on shares of Illumina from $247.00 to $128.00 and set an "outperform" rating for the company in a report on Wednesday, March 12th. TD Cowen downgraded shares of Illumina from a "buy" rating to a "hold" rating and decreased their target price for the company from $177.00 to $140.00 in a research report on Friday, February 7th. Finally, Guggenheim cut their price target on Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $140.90.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.